Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

Conditions:   Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   SomatostatinomaInterventions:   Drug: regorafenib;   Other: laboratory biomarker analysisSponsors:   University of Southern California;   National Cancer Institute (NCI)Not yet recruiting - verified March 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials